



LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

COMPLETION OF THE PROPOSED ACQUISITION OF 20% OF AFFINITY SURGERY CENTRE PTE. LTD.

The board of directors (“**Board**” or “**Directors**”) of Livingstone Health Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcement made by the Company on 21 November 2025, in relation to, *inter alia*, the Proposed Acquisition of 20% of Affinity Surgery Centre Pte. Ltd. (the “**Previous Announcement**”). Unless otherwise defined, all terms and references used herein shall bear the same meanings ascribed to them in the Previous Announcement.

Further to the Previous Announcement in connection with the Proposed Acquisition, the Revised Employment Agreement, the Management Agreement and Shareholders’ Agreement, had been entered into amongst the relevant parties on 28 November 2025.

Under the terms and conditions of the Shareholders’ Agreement, unless otherwise agreed upon in writing between the Purchaser (which is a wholly owned subsidiary of the Company) and the Vendor, in the event that the Revised Employment Agreement is terminated by the Vendor at any time for any reason whatsoever (the “**Termination Event**”), the Purchaser shall sell all of its shares in the Target at the material time, free from all encumbrances, to the Vendor at a price determined by an investment capital protection formula, and in accordance with and subject to the terms and conditions of the Shareholders’ Agreement (including compliance with applicable Catalist Rules). This mechanism is intended to safeguard the Purchaser’s investment in the event the Vendor exits. The sale shall be mandatory upon the occurrence of the Termination Event, unless the obligation for the sale no longer arises pursuant to the scenarios as set out in the Shareholders’ Agreement.

For the avoidance of doubt, no option is being granted to either the Purchaser or the Vendor in connection with the aforesaid sale of shares.

Based on the foregoing, the Board wishes to announce that the Proposed Acquisition has been completed as of 1 December 2025. Accordingly, the Target has become an associated company (as defined under the Catalist Rules) of the Company.

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
1 December 2025

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.